Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ptc Therapeutics (PTCT)

Ptc Therapeutics (PTCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,609,662
  • Shares Outstanding, K 82,775
  • Annual Sales, $ 1,731 M
  • Annual Income, $ 682,640 K
  • EBIT $ 892 M
  • EBITDA $ 914 M
  • 60-Month Beta 0.55
  • Price/Sales 3.29
  • Price/Cash Flow 7.83
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 71.62% (+0.76%)
  • Historical Volatility 40.72%
  • IV Percentile 92%
  • IV Rank 38.09%
  • IV High 128.79% on 04/24/25
  • IV Low 36.45% on 01/21/26
  • Expected Move (DTE 11) 2.55 (3.76%)
  • Put/Call Vol Ratio 0.08
  • Today's Volume 131
  • Volume Avg (30-Day) 109
  • Put/Call OI Ratio 0.21
  • Today's Open Interest 10,457
  • Open Int (30-Day) 10,915
  • Expected Range 65.22 to 70.32

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.36
  • Number of Estimates 6
  • High Estimate $-0.04
  • Low Estimate $-0.47
  • Prior Year $10.04
  • Growth Rate Est. (year over year) -103.59%

Price Performance

See More
Period Period Low Period High Performance
1-Month
61.43 +10.32%
on 03/06/26
71.00 -4.55%
on 03/10/26
+1.40 (+2.11%)
since 03/02/26
3-Month
61.43 +10.32%
on 03/06/26
80.18 -15.48%
on 01/13/26
-8.97 (-11.69%)
since 01/02/26
52-Week
35.95 +88.51%
on 05/06/25
87.50 -22.55%
on 11/26/25
+19.40 (+40.11%)
since 04/02/25

Most Recent Stories

More News
PTC Therapeutics Appoints Biotech Banking Pioneer Jessica Chutter to Board of Directors

WARREN, N.J. , March 25, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced the appointment of Jessica Chutter to its Board of Directors. Ms. Chutter is a highly accomplished...

PTCT : 67.77 (-1.43%)
PTC Therapeutics to Participate at Upcoming Investor Conferences

WARREN, N.J. , Feb. 23, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences:

PTCT : 67.77 (-1.43%)
PTC Therapeutics: Q4 Earnings Snapshot

PTC Therapeutics: Q4 Earnings Snapshot

PTCT : 67.77 (-1.43%)
PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

– Full-year 2025 product and royalty revenue of $831M, exceeding guidance –

PTCT : 67.77 (-1.43%)
PTC Therapeutics Provides Regulatory Update on Translarna™

WARREN, N.J. , Feb. 12, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it has withdrawn the New Drug Application (NDA) resubmission for Translarna™ (ataluren)...

PTCT : 67.77 (-1.43%)
PTC Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, Feb. 19, 2026

WARREN, N.J. , Feb. 5, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its fourth quarter and full year...

PTCT : 67.77 (-1.43%)
PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference

– Strong Sephience™ (sepiapterin) launch continues with unaudited Q4 global revenue of $92.5M –

PTCT : 67.77 (-1.43%)
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WARREN, N.J. , Jan. 8, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 2, 2026, the company approved 300 restricted stock units ("RSUs"), each representing...

PTCT : 67.77 (-1.43%)
PTC Therapeutics Announces Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) in Japan

– Indication includes all ages and the full spectrum of disease severity – – First Japan product approval for PTC –

PTCT : 67.77 (-1.43%)
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WARREN, N.J. , Dec. 19, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Dec. 16, 2025, the company approved non-statutory stock options to purchase an aggregate...

PTCT : 67.77 (-1.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of orally administered, small-molecule drugs for genetic disorders, oncology and infectious disease. PTC Therapeutics, Inc. is based in South Plainfield, United States.

See More

Key Turning Points

3rd Resistance Point 70.29
2nd Resistance Point 69.50
1st Resistance Point 68.63
Last Price 67.77
1st Support Level 66.97
2nd Support Level 66.18
3rd Support Level 65.31

See More

52-Week High 87.50
Fibonacci 61.8% 67.81
Last Price 67.77
Fibonacci 50% 61.72
Fibonacci 38.2% 55.64
52-Week Low 35.95

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.